Medical Use
FOLOTYN® (pralatrexate injection) is a dihydrofolate reductase inhibitor used to treat patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). This treatment received accelerated approval based on the overall response rate. Ongoing approval may depend on confirming and detailing the clinical benefits in further trials.
Warning & Precautions
Myelosuppression: FOLOTYN may lead to myelosuppression, presenting as thrombocytopenia, neutropenia, and/or anemia. Regularly monitor complete blood counts and adjust or omit the dose based on ANC and platelet levels.
Mucositis: FOLOTYN can cause mucositis. Conduct weekly monitoring and reduce or omit the dose for mucositis of grade 2 or higher.
Dermatologic Reactions: Dermatologic reactions, including severe and potentially fatal ones, may occur and worsen with continued treatment. Monitor closely and withhold or discontinue FOLOTYN based on the severity of the reaction.
Tumor Lysis Syndrome: FOLOTYN can induce tumor lysis syndrome. Monitor at-risk patients closely and treat promptly if it occurs.
Hepatic Toxicity: FOLOTYN can cause liver toxicity and abnormalities in liver function tests. Regularly monitor liver function, and adjust or discontinue the dose based on the severity of the toxicity.
Risk of Increased Toxicity with Renal Impairment: Patients with severe renal impairment may experience higher exposure and adverse reactions. Reduce the FOLOTYN dose for these patients and avoid use in those with end-stage renal disease, with or without dialysis. If treatment is necessary, monitor renal function and adjust the dose accordingly.
Embryo-Fetal Toxicity: FOLOTYN can harm a fetus. Advise patients of the potential risks and recommend effective contraception for females of reproductive potential during treatment and for six months after the last dose. Males with partners of reproductive potential should use effective contraception during treatment and for three months after the last dose.
The most common serious adverse reactions occurring in more than 3% of patients were pyrexia, mucositis, sepsis, febrile neutropenia, dehydration, dyspnea, and thrombocytopenia.
Documentation Availability
Documents required to import Folotyn to India?
Folotyn can be imported by patients or treating physicians on behalf of patients. The following documentation is required to import the product:
- (i)2 ID proofs along with PAN card details along with attested scanned copies
- (ii)Valid doctor prescription scanned copy
- (iii)Doctor’s MCI number
- (iv)Doctor’s mobile number
- (v)Patients diagnostic reports
How is the order confirmed?
The order will be confirmed only after the receipt of:
- (i)The above-mentioned documents and drug availability.
- (ii)Import permit if applicable.
Sourcing & Delivery
The Rx4U team has extensive experience in sourcing FOLOTYN (Cancer Treatment Medicines) around the world, ensuring global access to the best available treatments for our customers. We are dedicated to promptly dispensing any valid prescription. All prescriptions are verified and dispatched directly to the patient’s address. Our patients are our top priority, and we strive to improve their lives through our services.
FAQ
What is the generic name for the trade name drug Folotyn?
The generic name for Folotyn is pralatrexate.
Who manufactures Folotyn?
Folotyn is manufactured by Allos Therapeutics, Inc.
Is Folotyn approved by the FDA?
Yes, Folotyn received FDA approval on September 24, 2009.
What dosage and form is Folotyn available in?
Folotyn is available in a dosage of 40 mg/2 ml.
How to order Folotyn online in India?
Folotyn can be ordered online in India through https://rx4u.in/.
*Disclaimer
All Trademarks and Brands that appear on the website belong to their respective owners and Rx4U does not lay any claim on them we only provide Information.
